BioCentury | Jun 18, 2018
Company News

Management tracks: Ionis, Albireo

...company Alkahest Inc. (San Carlos, Calif.) hired Michael Byrnes as CFO. He was CFO at Ocera Therapeutics Inc....
BioCentury | Jan 12, 2018
Company News

Mallinckrodt divests hemostasis portfolio for $185M

...needs, including StrataGraft and terlipressin, as well as products gained through its recent acquisition of Ocera Therapeutics Inc....
...Raplixa, from The Medicines Co. (NASDAQ:MDCO) in 2016. Last month, Mallinckrodt closed its acquisition of Ocera...
BioCentury | Nov 30, 2017
Company News

Mallincrodt acquiring Ocera

...$1.52 per share in a deal the companies say values Ocera at about $42 million. Ocera's...
...or about $75 million, upon achievement of milestones. The price is a 52% premium to Ocera’s...
...Ocera Therapeutics Inc. (NASDAQ:OCRX), Redwood City, Calif. Mallinckrodt plc (NYSE:MNK), Staines-upon-Thames, U.K. Business: Hepatic Alicia Parker IV OCR-002 oral OCR-002 Mallinckrodt plc Ocera Therapeutics Inc....
BioCentury | Feb 3, 2017
Clinical News

IV OCR-002: Ph IIb STOP-HE data

...hospital discharge. Patients received SOC plus placebo or 10, 15 or 20 mg IV OCR-002. Ocera Therapeutics Inc....
...to complete response in hepatic encephalopathy symptoms Status: Phase IIb data Milestone: NA Jaime De Leon IV OCR-002 Ocera Therapeutics Inc. IV...
BioCentury | Dec 21, 2016
Clinical News

IV ornithine phenylacetate: Completed Ph IIb STOP-HE enrollment

...IV OCR-002 over 24 hours for up to 5 days plus standard of care (SOC). Ocera Therapeutics Inc....
...and Glasgow Coma Scale Status: Completed Phase IIb enrollment Milestone: Phase IIb data (1Q17) Chris Lieu IV OCR-002 Ocera Therapeutics Inc. IV...
BioCentury | Dec 2, 2016
Clinical News

Ornithine phenylacetate: Ph IIa STOP-ALF data

...well tolerated at all doses (3.33-20 g/24 hours), with no treatment-related serious adverse events reported. Ocera...
...at the American Association for the Study of Liver Diseases meeting in Boston. Next quarter, Ocera...
...patients with cirrhosis. Data from part 1 of the trial are expected by year end. Ocera Therapeutics Inc....
BioCentury | Sep 26, 2016
Clinical News

Ornithine phenylacetate: Phase I started

...part are expected next half. IV OCR-002 is in Phase IIb testing to treat HE. Ocera Therapeutics Inc....
BioCentury | Sep 26, 2016
Clinical News

Ornithine phenylacetate: Completed Phase IIa enrollment

...Phase IIa STOP-ALF trial evaluating 3.33-20 g/24 hours IV OCR-002 for up to 120 hours. Ocera Therapeutics Inc....
BioCentury | Jan 18, 2016
Clinical News

Ornithine phenylacetate: Phase I data

...IIb STOP-HE trial to treat acute hepatic encephalopathy in hospitalized patients with elevated ammonia levels. Ocera Therapeutics Inc....
BioCentury | Sep 28, 2015
Clinical News

Ornithine phenylacetate: Phase I started

...IV formulation of the product is in Phase II trials to treat acute hepatic encephalopathy. Ocera Therapeutics Inc....
Items per page:
1 - 10 of 73
BioCentury | Jun 18, 2018
Company News

Management tracks: Ionis, Albireo

...company Alkahest Inc. (San Carlos, Calif.) hired Michael Byrnes as CFO. He was CFO at Ocera Therapeutics Inc....
BioCentury | Jan 12, 2018
Company News

Mallinckrodt divests hemostasis portfolio for $185M

...needs, including StrataGraft and terlipressin, as well as products gained through its recent acquisition of Ocera Therapeutics Inc....
...Raplixa, from The Medicines Co. (NASDAQ:MDCO) in 2016. Last month, Mallinckrodt closed its acquisition of Ocera...
BioCentury | Nov 30, 2017
Company News

Mallincrodt acquiring Ocera

...$1.52 per share in a deal the companies say values Ocera at about $42 million. Ocera's...
...or about $75 million, upon achievement of milestones. The price is a 52% premium to Ocera’s...
...Ocera Therapeutics Inc. (NASDAQ:OCRX), Redwood City, Calif. Mallinckrodt plc (NYSE:MNK), Staines-upon-Thames, U.K. Business: Hepatic Alicia Parker IV OCR-002 oral OCR-002 Mallinckrodt plc Ocera Therapeutics Inc....
BioCentury | Feb 3, 2017
Clinical News

IV OCR-002: Ph IIb STOP-HE data

...hospital discharge. Patients received SOC plus placebo or 10, 15 or 20 mg IV OCR-002. Ocera Therapeutics Inc....
...to complete response in hepatic encephalopathy symptoms Status: Phase IIb data Milestone: NA Jaime De Leon IV OCR-002 Ocera Therapeutics Inc. IV...
BioCentury | Dec 21, 2016
Clinical News

IV ornithine phenylacetate: Completed Ph IIb STOP-HE enrollment

...IV OCR-002 over 24 hours for up to 5 days plus standard of care (SOC). Ocera Therapeutics Inc....
...and Glasgow Coma Scale Status: Completed Phase IIb enrollment Milestone: Phase IIb data (1Q17) Chris Lieu IV OCR-002 Ocera Therapeutics Inc. IV...
BioCentury | Dec 2, 2016
Clinical News

Ornithine phenylacetate: Ph IIa STOP-ALF data

...well tolerated at all doses (3.33-20 g/24 hours), with no treatment-related serious adverse events reported. Ocera...
...at the American Association for the Study of Liver Diseases meeting in Boston. Next quarter, Ocera...
...patients with cirrhosis. Data from part 1 of the trial are expected by year end. Ocera Therapeutics Inc....
BioCentury | Sep 26, 2016
Clinical News

Ornithine phenylacetate: Phase I started

...part are expected next half. IV OCR-002 is in Phase IIb testing to treat HE. Ocera Therapeutics Inc....
BioCentury | Sep 26, 2016
Clinical News

Ornithine phenylacetate: Completed Phase IIa enrollment

...Phase IIa STOP-ALF trial evaluating 3.33-20 g/24 hours IV OCR-002 for up to 120 hours. Ocera Therapeutics Inc....
BioCentury | Jan 18, 2016
Clinical News

Ornithine phenylacetate: Phase I data

...IIb STOP-HE trial to treat acute hepatic encephalopathy in hospitalized patients with elevated ammonia levels. Ocera Therapeutics Inc....
BioCentury | Sep 28, 2015
Clinical News

Ornithine phenylacetate: Phase I started

...IV formulation of the product is in Phase II trials to treat acute hepatic encephalopathy. Ocera Therapeutics Inc....
Items per page:
1 - 10 of 73